Creative Disruption Forum (CDF)

Want to hear what sector’s most influential thinkers say about where AI and next-gen therapies are heading in 2026?

AI is rapidly reshaping emerging biotech, advanced therapies and biologics in the UK. Machine learning now enables the analysis of large and complex datasets, supporting the discovery of new biomarkers and therapeutic targets and improving the modelling of biological responses. This leads to more precise and better targeted biologics and advanced therapies.

UK biotech organisations are also forming deeper partnerships with technology companies to access advanced data analytics and embed AI more effectively into research pipelines. Government backed initiatives are strengthening this progress and accelerating innovation.

AI driven drug repurposing is gaining momentum, helping redirect existing compounds to new indications, reducing development timelines and improving cost efficiency. With these advances accelerating, the UK remains strongly positioned to lead in biologics and advanced therapies both scientifically and commercially.

Chatham House Rules apply - "what goes on in the Forum, stays in the Forum - so to speak!"

Who Should Attend

The #CreativeDisruption Forum is designed for professionals working in life sciences who are driving innovation and growth, such as business and research leaders.